Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). (Q53352094)

13 May 2018

review article

1 reference

title

Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). (English)

1 reference

13 May 2018

author name string

E Holme

series ordinal

1

1 reference

13 May 2018

S Lindstedt

series ordinal

2

1 reference

13 May 2018

publication date

1 August 1998

1 reference

13 May 2018

Journal of Inherited Metabolic Disease

published in

1 reference

13 May 2018

volume

21

1 reference

13 May 2018

page(s)

507-517

1 reference

13 May 2018

issue

5

1 reference

13 May 2018

https://scigraph.springernature.com/pub.10.1023/a:1005410820201

exact match

0 references

cites work

Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect

1 reference

12 December 2020

Neurologic crises in hereditary tyrosinemia

1 reference

12 December 2020

Steady state kinetics of 4-hydroxyphenylpyruvate dioxygenase from human liver (III)

1 reference

12 December 2020

The occurrence of hepatoma in the chronic form of hereditary tyrosinemia

1 reference

12 December 2020

On the enzymic defects in hereditary tyrosinemia

1 reference

12 December 2020

Self-induced correction of the genetic defect in tyrosinemia type I

1 reference

12 December 2020

Diagnosis and management of tyrosinemia type I.

1 reference

12 December 2020

From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug

1 reference

12 December 2020

Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase

1 reference

12 December 2020

Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment.

1 reference

12 December 2020

Complete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway

1 reference

12 December 2020

Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione

1 reference

12 December 2020

Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I.

1 reference

12 December 2020

Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC)

1 reference

12 December 2020

Peripheral neuropathy as the presenting feature of tyrosinaemia type I and effectively treated with an inhibitor of 4-hydroxyphenylpyruvate dioxygenase

1 reference

12 December 2020

Liver transplantation in nine Spanish patients with tyrosinaemia type I

1 reference

12 December 2020

Tyrosinaemia type I: orthotopic liver transplantation as the only definitive answer to a metabolic as well as an oncological problem

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1005410820201

1 reference

13 May 2018

Dimensions Publication ID

0 references

1 reference

13 May 2018